Premium
Response of astrocytoma to high‐dose methotrexate with citrovorum factor rescue
Author(s) -
Djerassi Isaac,
Kim Jung Sun,
Reggev Avner
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850615)55:12<2741::aid-cncr2820551202>3.0.co;2-2
Subject(s) - medicine , methotrexate , astrocytoma , surgery , disease , glioblastoma , cancer research
Eleven patients with astrocytoma were treated with high‐dose methotrexate (HDMTX) and citrovorum factor rescue (CFR). Clinical response was observed in eight patients, including four of four with grade 3 disease, one of one with grade 2 to 3, two of four with grade four, and one of one with unspecified low‐grade tumor. Two patients with grade 4 and one with grade 1 disease failed to respond. Six of the eight responses were documented radiographically. Three of these patients are alive and well without further treatment for periods of 15+, 4.5+, and 1.5+ years. The fourth living patient is surviving 2+ years and improving under continued treatment. The four surviving patients had recurrent grade 2 to 3 or grade 3 disease. HDMTX‐CFR is effective in astrocytoma. Its greatest value may be in recurring grade 3 disease.